Meeting
2014 Gastrointestinal Cancers Symposium
Management of Peritoneal Malignancies
Presenter
David P. Ryan, MD
Massachusetts General Hospital Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Meet the Professor Session
Session Title
Management of Peritoneal Malignancies
Track
Cancers of the Colon, Rectum, and Anus,Cancers of the Esophagus and Stomach,Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
Speaker: Hidetoshi Hayashi, MD, PhD
Videos & Slides
2017 ASCO Annual Meeting
Osimertinib compared to docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small cell lung cancer.
Speaker: Keke Nie
Videos & Slides
2014 ASCO Annual Meeting
Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).
Speaker: Dong-Wan Kim, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.
Speaker: Helena Alexandra Yu, MD